Blood Coagulation Tests Clinical Trial
Oral anticoagulants are increasingly prescribed and the are not discontinued for invasive
cardiac procedures .
Additional parenteral anticoagulation is necessary for these procedures (FA ablation and
invasive coronary explorations).
The unfractionated heparin doses are adapted on a monitoring test heparin, activated clotting
time (ACT) with the aim of obtaining and maintaining an ACT > 300-400 sec. This goal is the
same whether the patient is on oral anticoagulant treatment or not, and regardless of the
initial level of anticoagulation.
The effects of oral anticoagulants on routine coagulation tests (PT, APTT, TT) are well
documented, but few data have been published on the effects of heparin monitoring tests,
particularly on the ACT.
The aim of this stuy is to redefine the target values of ACT and unfractionated heparin doses
to administer to optimize the efficacy / safety of invasive procedures in cardiology.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT03647254 -
Efficacy of a Didactic Intervention in Anticoagulated Patients (TAOPE Study)
|
N/A | |
| Unknown status |
NCT02255214 -
Evaluation of the Accuracy of the Hemochron Signature Elite Point of Care Device Compared With Laboratory Assay
|
N/A | |
| Completed |
NCT01588327 -
A Prospective Pharmacodynamic Study of Dabigatran
|
N/A | |
| Completed |
NCT03280368 -
Adherence and Coagulation Assays in Dabigatran-treated Patients With Atrial Fibrillation
|
||
| Recruiting |
NCT01167660 -
Non Invasive Measurement of Coagulation in Term and Preterm Neonates
|
N/A |